In this manuscript, we describe the creation of a CD99-targeted imaging probe that is highly sensitive for the visualization of CD99-expressing tumors. The 64 Cu-labeled anti-CD99 probe is able to visualize 1-2 mm lesions, in xenograft models of Ewing sarcoma micrometastases, below the threshold of detection using FDG-PET. The performance of the current probe establishes a rationale for the development of a CD99 Research.
INTRODUCTION
Author Manuscript Published OnlineFirst on November 11, 2013; DOI: 10.1158/1078-0432.CCR- probe. Micrometastatic disease that cannot be detected with existing imaging modalities is a known risk for distant recurrence, hence the need exists for new imaging approaches that can more accurately identify remote sites of disease with high specificity and sensitivity. (11) Imaging also plays a primary role in assessing the response of patients to therapy. After completion of therapy, patients typically undergo surveillance with MRI of the primary disease site as well as chest CT, or serial chest X-rays, for evaluation of pulmonary nodules, a common site of disease recurrence. (12) Although CT imaging is excellent at detecting abnormal lung lesions of small size, it cannot accurately distinguish between scar tissue, vascular structures, inflammation, infection and malignant disease. A targeted imaging approach for Ewing sarcoma would help alleviate the diagnostic quandary posed by the finding of small lung nodules detected using existing imaging approaches, both at the time of diagnosis and during post-treatment surveillance.
By routine histological staining, Ewing sarcoma cells are similar to other so-called "small round blue cell tumors." The most specific diagnostic marker used for the histopathological diagnosis of Ewing sarcoma is CD99 (MIC2), a 32-kDa integral membrane glycoprotein that is highly expressed in Ewing sarcoma. (13, 14) CD99 plays a key role in cell adhesion, migration, and apoptosis in lymphocytes, and appears to affect differentiation and malignancy of Ewing cells. (15, 16) In clinical Ewing sarcoma cancer specimens, immunohistochemical staining of CD99 demonstrates high expression in a diffuse membrane distribution with nearly 100% of specimens staining positive, speaking to its use as a diagnostic tool. (17) CD99 is also expressed on circulating leukocytes; however, the degree of CD99 expression in white blood cells as compared with Ewing sarcoma cells is not well described. (18, 19) Research. Given a known high level of expression of CD99 at the cell surface in Ewing sarcoma, we sought to create an imaging probe targeting CD99 to allow detection of Ewing sarcoma micrometastases in a more sensitive and specific manner than is possible with existing imaging modalities. While therapeutic studies have targeted CD221 (insulin-like growth factor receptor), a well-researched Ewing sarcoma cell surface protein, we opted to focus on CD99 given that expression of CD221 has been shown to be variable. (20) Given the routine use of PET imaging at diagnosis and during surveillance, we chose to develop a 64 Cu-labeled anti-CD99 antibody, which may have utility not only in Ewing sarcoma, but other cancers in which CD99 is over-expressed, including lymphomas, synovial cell sarcoma, rhabdomyosarcoma, spindle cell tumors, and other soft tissue sarcomas. (21, 22) 
METHODS AND MATERIALS
Cell Culture and Flow Cytometry: TC32 Ewing sarcoma cells (CD99+) were cultured in RPMI (Gibco); A673 Ewing sarcoma cells (CD99+) and Kelly neuroblastoma cells (CD99-) were cultured in DMEM, all supplemented with 10% FBS and 1% penicillinstreptomycin (Gibco) in 5% CO 2 at 37°C. A673 and TC32 cell lines were provided by Dr.
Todd Golub (Broad Institute, Cambridge, MA). The Kelly cell line was provided by Dr.
Rani George (Dana-Farber Cancer Institute, Boston, MA). All Ewing sarcoma cell lines were authenticated via confirmation of a translocation of EWS and FLI1 genes by FISH for disruption of the EWS locus, and RT-PCR cloning of the fusion junction (data not shown). TC32 cells were transduced with a lentivirus containing the FUW-LucmCherry-puro construct to enable bioluminescence imaging (BLI). Research. Cu: Chemicals and reagents were obtained from SigmaAldrich (St. Louis, MO) unless otherwise specified. EDC (1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride) was purchased from Pierce (Rockford, IL). Metal-naïve pipette tips were purchased from Rainin Instrument (Oakland, CA) and were used to prepare all samples. Glass and plasticware were acid washed with 10% HNO 3 and rinsed thoroughly with ultra-pure water (>15 MΩ resistivity; US Filter/Siemens Water Technologies, Warrendale, PA). Ultra-pure water was also used in all buffer preparations. Metal contaminants in buffers were decreased by passing through a Chelex-100 resin column (Bio-Rad Laboratories, Hercules, CA). For radiolabeling, conjugated antibody aliquots were thawed, mixed with 64 Cu at a ratio of 4:1 (µCi/µg) and incubated for 30 min at 25°C. Thin layer chromatography (TLC) was used to assess radiolabeling. An aliquot (1 µL) of the radiolabeling reaction was added to 9 µL of phosphate buffer (0.1 M, pH 8, 100 mM EDTA). After 5 min, a 1 µL aliquot of the mixture was spotted on an instant TLC glass microfiber strip (Biodex Medical Systems, Inc., NY), allowed to dry, and developed using phosphate buffer/EDTA as the mobile phase. Using these conditions, the radiolabeled antibody remains at the baseline and free 64 Cu moves with the solvent front. The TLC strip was cut in half and the radioactivity in each half was assayed. If the TLC assay showed that the radiochemical purity was <95%, the product was purified using centrifugal filter units (as described above). The radioimmunoconjugate was diluted with saline and sterile filtered (0.2 µM filter) before injection. MRI imaging: Mice were imaged with a Bruker 7T BioSpec system. Mice were anesthetized with 1-1.5% isoflurane and rapid acquisition with relaxation enhancement (RARE) methods were used to obtain the images with TR=1200ms, effective TE=20ms, in plane geometry: FOV=25.6x19.2mm, matrix size=256x192, and slice thickness=1mm.
Research.
on April (Figure 2A) Cu-DN16 probe, tracer background was restricted to the blood pool ( Figure 2C ).
RESULTS

Immunostaining
Together, these results demonstrate that the staining in Ewing sarcoma cells was diffuse, membranous, and qualitatively more intense ( Figure 6C, top row) .
DISCUSSION
In the clinic, imaging plays a key role in the management of patients with solid tumors, helping to determine the primary site of disease, sites of dissemination, and response to therapy. While some forms of cancer utilize surgical sampling to determine the extent of local spread (e.g., regional lymph node sampling), in most cases imaging is the only modality used to determine whether distant metastases are present. Despite tremendous advances in the last few decades, the clinical limit of detection of current imaging modalities is on the order of 5-10 mm.(6-10) Moreover, lesions in this size range are often indistinguishable from non-malignant processes, resulting in uncertainty in interpretation. There is thus an unmet need for more sensitive and specific cancer imaging approaches.
Molecular imaging sensitivity is directly dependent on system resolution as well as other characteristics of the scanner and, equally important, the tumor (signal)-to-background ratio provided by the imaging probe. In these experimental models, our data show that small lesions detectable with preclinical MRI cannot be detected using preclinical FDG-PET but can be detected using the same PET scanner with the 64 Cu-labeled anti-CD99 antibody probe. Preclinical imaging devices offer superior resolution to clinical PET scanners, therefore it may be difficult to extrapolate these results to the clinical realm.
However, we anticipate that this targeted imaging approach will translate to a similarly improved signal-to-background ratio when used with human scanners, leading to enhanced detection of metastatic lesions, and ultimately tailored therapy for patients with Ewing sarcoma. There are multiple requirements for the development of an antibody-targeted imaging probe. First, the epitope of interest must be extracellular and must be expressed at high levels. Second, the radionuclide should have a sufficiently long half-life to allow delayed imaging to match the pharmacokinetic properties of intact antibodies. Finally, for clinical use, the antibody must be humanized to allow repeated use. The radionuclide dose in humans, extrapolated from standard Cu-labeled anti-CD99 radioconjugate is both sensitive and specific for PET imaging of Ewing sarcoma in experimental models.
These encouraging first results establish the rationale for proceeding with development of a human probe for future clinical translation.
Assessment of specificity in xenograft models is confounded by lack of cross-species reactivity for most antibodies. Moreover, CD99 is normally expressed on leukocytes and is highly expressed on thymocytes, where it is believed to augment T-cell adhesion, apoptosis of double positive T-cells, and migration and activation. (18) The immunodeficient animals used in this study lack lymphocytes, limiting the ability to assess whether the antibody is cross-reactive. To this end, we stained normal human lymphocytes and found that only a small fraction of total lymphocytes stain positive for CD99, and that this staining is quantitatively lower than that for Ewing sarcoma cells.
We also performed immunohistochemistry on paraffin-embedded human Ewing sarcoma versus human lymph node specimens to determine the relative expression of CD99 in clinical specimens. We again found that a much higher proportion of Ewing sarcoma cells stain positive for CD99 and that the staining is far more intense than for lymphoid tissues. These results suggest that the level of expression of CD99 in Ewing sarcoma 
